Background/Aims: Glycine plays an important role in regulating hippocampal inhibitory/ excitatory neurotransmission through activating glycine receptors (GlyRs) and acting as a coagonist of N-methyl-d-aspartate-type glutamate receptors. Activation of transient receptor potential vanilloid 4 (TRPV4) is reported to inhibit hippocampal A-type γ-aminobutyric acid receptor, a ligand-gated chloride ion channel. GlyRs are also ligand-gated chloride ion channels and this paper aimed to explore whether activation of TRPV4 could modulate GlyRs. Methods: Whole-cell patch clamp recording was employed to record glycine-activated current (I Gly ) and Western blot was conducted to assess GlyRs subunits protein expression. Results: Application of TRPV4 agonist (GSK1016790A or 5,6-EET) increased I Gly in mouse hippocampal CA1 pyramidal neurons. This action was blocked by specific antagonists of TRPV4 (RN-1734 or HC-067047) and GlyR (strychnine), indicating that activation of TRPV4 increases strychninesensitive GlyR function in mouse hippocampal pyramidal neurons. GSK1016790A-induced increase in I Gly was significantly attenuated by protein kinase C (PKC) (BIM II or D-sphingosine) or calcium/calmodulin-dependent protein kinase II (CaMKII) (KN-62 or KN-93) antagonists but was unaffected by protein kinase A or protein tyrosine kinase antagonists. Finally, hippocampal protein levels of GlyR α1 α2, α3 and β subunits were not changed by treatment with GSK1016790A for 30 min or 1 h, but GlyR α2, α3 and β subunits protein levels increased in mice that were intracerebroventricularly (icv.) injected with GSK1016790A for 5 d. Conclusion:
Introduction
Transient receptor potential vanilloid 4 (TRPV4) is a member of the transient receptor potential superfamily [1] . TRPV4 displays a widespread expression in the central nervous system (CNS), including in the cortex, thalamus, hippocampus and cerebellum [2] . Activation of TRPV4 induces calcium (Ca 2+ ) influx and depolarizes the cell membrane [3] . In addition, activation of TRPV4 can modulate voltage-gated ion channels (such as voltage-gated sodium, potassium and calcium channels) and ligand-gated ion channels (such as N-methyl-Daspartate (NMDA)-and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors, transient receptor potential vanilloid 1 (TRPV1) receptors and A-type γ-aminobutyric acid (GABA A ) receptors) [4] [5] [6] [7] [8] [9] . These reports indicate that TRPV4 is an important target for controlling cellular excitability.
Accumulating evidence has shown that activation of TRPV4 leads to an increase in neuronal excitability [10, 11] . In the CNS, the balance between excitatory and inhibitory neurotransmitter systems plays an important role in modulating neuronal excitability. Activation of TRPV4 may promote pre-synaptic glutamate release and increase postsynaptic glutamate receptors to enhance glutamatergic transmission in the hippocampus [7, 8, 12] . TRPV4 expressed in the astrocytes has been identified to be responsible for initiating excitatory gliotransmitter release to enhance hippocampal synaptic transmission in mouse [13] . Therefore, activation of TRPV4 may facilitate the excitatory neurotransmitter system function. GABA and glycine are two main inhibitory neurotransmitters that act through ligand-gated chloride ion (Cl -) channels and mediate inhibitory neurotransmission [14, 15] . GABAergic neurotransmission predominates in all brain regions through activation of A-type ionotropic GABA receptors (GABA A Rs). Glycine also mediates fast inhibitory transmission via ionotropic glycine receptors (GlyRs), which predominates in the spinal cord and brainstem [14, 16] . Furthermore, GlyRs have been proven to be functionally expressed in the hippocampus of rodents [17] . Activation of GlyRs limits activity in the synaptic network by depressing suprathreshold excitatory postsynaptic potentials to subthreshold events in recordings from both CA1 pyramidal cells and interneurons [18] . GlyRs are also involved in glycine-induced long-term depression of excitatory postsynaptic currents in hippocampal CA1 pyramidal neurons [19] . In addition to the inhibition mediated through GlyRs per se, there is evidence about the interactions between GABAergic and glycinergic neurotransmission. The cross-inhibition between GlyRs and GABA A Rs has been revealed in olfactory bulb cells, spinal dorsal horn neurons and hippocampal pyramidal neurons [17, 20, 21] . Therefore, GlyRs may play an important role in modulating hippocampal synaptic and network plasticity.
In our recent study, GABA-induced current recorded in hippocampal neurons was inhibited by application of TRPV4 agonists, indicative of down-regulation of GABA A Rs [6] . GlyRs are also ligand-gated chloride ion channels, but whether they can be modulated by TRPV4 activation remains unknown. Studies have proven that GlyRs can be phosphorylated by various protein kinases such as protein kinase A (PKA), protein kinase C (PKC), calcium/ calmodulin-dependent protein kinase II (CaMKII) and protein tyrosine kinase (PTK) [22] [23] [24] . In our previous studies, activation of TRPV4 modulated voltage-and ligand-gated ion channels via intracellular signaling (PKA, PKC, CaMKII, ect.) [4] [5] [6] [7] [8] [9] . In this study, we examined whether glycine-activated current (I Gly ) in mouse hippocampal neurons and GlyR subunit expression in hippocampi could be modulated by TRPV4 activation and further explored the possible mechanisms underlying TRPV4 action.
Whole-cell patch clamp recording
Hippocampal CA1 pyramidal neurons were perfused continually with oxygenated ACSF at room temperature (22-23ºC ). An EPC-10 amplifier (HEKA Elektronik, Lambrecht/Pfalz, Germany) was used to record and amplify I Gly . The sampling rate was 10 kHz and filtered (Bessel) at 2.9 kHz. The capacitance and series resistance were compensated to 90%. 0.3 μM tetrodotoxin (TTX) was added to the ACSF to block TTX-sensitive voltage-gated sodium current. Glycine was dissolved in the ACSF and was focally applied using a rapid drug delivery system directed toward the soma of the recorded neurons. The holding potential was -60 mV and the glass pipettes resistance was 1-3 MW. The pipette solution was composed of (in mM) CsCl 140, CaCl 2 0.5, MgCl 2 3, EGTA 5, HEPES 10, and Tris-ATP 5 at pH 7.25. The expression of TRPV4 in hippocampal CA1 pyramidal neurons was functionally verified if TRPV4 agonist (1 μM GSK1016790A or 500 nM 5, 6-EET)-induced current was recorded.
Drug treatment
In the previous studies, TRPV4 agonist was intracerebroventricularly (icv.) injected to activate TRPV4 in vivo [25, 26] . Here, the TRPV4 agonist GSK1016790A was injected (icv.) as previously reported [6] . After the mice (male, 9-10 weeks old) were anesthetized with 2% chloral hydrate (20 ml/kg), they were placed in a stereotactic device (Kopf Instruments, Tujunga, CA). With the help of a stepper motor-controlled microsyringe (Stoelting, Wood Dale, IL, USA), GSK1016790A (1 μM/2 μl/mouse) was injected into the right lateral ventricle (0.3 mm posterior, 1.0 mm lateral, and 2.5 mm ventral to the bregma) at a rate of 0.2 μl/min. GSK1016790A was injected once daily for 5 consecutive days (GSK1016790A-injected mice). Control mice were administered an equal volume of vehicle.
Western blot
Hippocampi were quickly collected after the slices were perfused with GSK1016790A or 12 h after the last icv. injection of GSK1016790A. Then hippocampi were homogenized in a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride and a protease inhibitor cocktail (Complete; Roche, Mannheim, Germany). Protein concentrations were determined using a bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Rochford, IL, USA). Total proteins (40 μg) were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and were then transferred to a polyvinylidene difluoride (PVDF) membrane. The membrane was incubated with 5% nonfat dry milk in Tris-buffered saline/0.1% Tween 20 (TBST) for 1 h at room temperature and was then incubated with an anti-α1 glycine receptor (Cat: ab166935, 1:1000, Abcam, Cambridge, UK), anti-α2 glycine receptor (Cat: ab97628, 1:1000, Abcam, Cambridge, UK), anti-α3 glycine receptor (Cat: ab118924, 1:1000, Abcam, Cambridge, UK), anti-β glycine receptor (Cat: AGR-014, 1:200, Alomone Labs Ltd, Jerusalem, Israel) or anti-glyceraldehyde 3-phosphate dehydrogenase (anti-GAPDH) antibody (Cat: ab181602, 1:5000; Abcam, Cambridge, UK) at 4°C overnight. After being washed with TBST for three times, the membrane was incubated with a horseradish peroxidase 
Data analysis
All I Gly data were acquired from neurons in which both I Gly and TRPV4 agonist-evoked current could be recorded. To examine the concentration-dependent response of GlyRs, I Gly induced by 10, 30, 50, 100 and 300 μM glycine was normalized to the current induced by 300 μM glycine in the same neuron. The data were fitted to the logistic equation I=I max /[1+(EC 50 /C) n ], where n is the Hill coefficient and EC 50 value is the concentration of glycine required for a half-maximal response. To examine the current-voltage relationship (I−V curve) of I Gly , I Gly induced at different holding potentials (-80, -40, -20, 0, +20, +40 and +60 mV) was normalized to the current induced at a holding potential of -60 mV in the same neuron. Data were expressed as means ± S.E.M. and analyzed using PulseFit (HEKA Elektronik) and Stata 7.0 software (STATA Corporation, USA). Statistical analysis was performed using paired or unpaired t test. Differences at P<0.05 or P<0.01 were considered statistically significant.
Chemicals
TTX was obtained from Enzo Life Science (Ann Arbor, MI, USA). PKI and 5(6)-epoxy-8Z,11Z,14Z-eicosatrienoic acid (5, 6-EET) were obtained from Cayman Chemical (Ann Arbor, MI, USA). All other chemicals were obtained from Sigma Chemical Company. GSK1016790A, RN1734, HC-067047, D-sphingosine, bisindolylmaleimide II (BIM II), phorbol 12-myristate 13-acetate (PMA), H-89, PKI, 8-bromoadenosine 3',5'-cyclic monophosphate sodium salt (8-Br-cAMP), lavendustin A, genistein, KN62 and KN93 were prepared as stock solutions in dimethyl sulfoxide (DMSO). The final concentration of DMSO in the bath solution or pipette solution was <0.1%. GSK1016790A, 5, 6-EET, RN1734, HC-067047, BIM II, PMA, 8-BrcAMP, lavendustin A, genistein, picrotoxin and strychnine were extracellularly applied by being added to the bath solution and to the rapid drug delivery system. The slices were pre-incubated with these chemicals for at least 5-8 min before recording I Gly . D-sphingosine, H-89, PKI, KN62 and KN93 were present in the pipette solution and pre-applied by dialysis into the neurons through the pipette. The concentrations of these drugs were chosen according to previous reports [6, [27] [28] [29] [30] .
Results

Effect of TRPV4 agonists on I Gly in mouse hippocampal CA1 pyramidal neurons
GSK1016790A is a commonly used synthetic TRPV4 agonist [31] . In this study, GSK1016790A was first used to evaluate the effect of TRPV4 activation on I Gly . As shown in Fig. 1A , I Gly (activated by 50 μM glycine) was reversibly increased by GSK1016790A (1 μM) and this effect was unlike the inhibitory effect of TRPV4 activation on GABA A Rs [6] . The average I Gly was -14.35±1.27 pA/pF, -21.57±0.98 pA/pF and -15.75±1.76 pA/pF before, during and after GSK1016790A treatment, respectively. GSK1016790A-induced increase in I Gly was concentration-dependent when GSK1016790A concentrations ranging from 0.1 to 10 μM, with an EC 50 value of 1.15±0.46 μM (Fig. 1B) . Here, I Gly was increased 32.48±2.08% by 1 μM GSK1016790A (n=35, paired t test, P<0.01) (Fig. 1B) , and this concentration was used in the subsequent experiments.
The effect of GSK1016790A on the concentration-response curve for I Gly is shown in Fig.  1C . The EC 50 and n values of the concentration-response curve in the control group were 79.15±6.13 μM and 2.11, respectively. The maximal response to 300 μM glycine was enhanced by GSK1016790A (n=9, paired t test, P<0.01), but EC 50 (76.55±5.88 μM) and n (2.16) values were unaffected (unpaired t test, P>0.05 in each case). Based on the concentration-response curve, 50 μM glycine was used to activate I Gly in the following experiments. The effect of GSK1016790A on the I−V curve of I Gly is shown in Fig. 1D . When the holding potential ranged from −80 mV to +60 mV, I Gly was increased by the application of GSK1016790A. The reversal potential was 8.16±0.34 mV and 8.38±0.40 mV, and the ratio of current at +60/-80 Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry mV (I +60mV /I −80mV ) was -0.60±0.01 and-0.59±0.03 in the control and GSK1016790A-treated groups, respectively (n=10, paired t test, P>0.05 in each case; Fig. 1d ). 5, 6-EET, a metabolite of arachidonate, has been reported as a natural TRPV4 agonist [31] . The effect of 5, 6-EET on I Gly is shown in Fig. 2 . I Gly was increased from -14.27±2.12 pA/ pF to -19.85±1.78 pA/pF by 500 nM 5, 6-EET (n=26, paired t test, P<0.01) and recovered to -15.51±2.47 after 5, 6-EET was washed out ( Fig. 2A and 2B ). In the concentration-response curve for I Gly, 5, 6-EET increased the maximal current activated by 300 μM glycine (n=9, paired t test, P<0.01), but did not change the EC 50 value (77.47±5.92 μM) or n (2.14) value (unpaired t test, p>0.05 in each case) (Fig. 2C) . Application of 5, 6-EET treatment did not A. I Gly (activated by 50 µM glycine) was increased from -655.12 pA to -855.74 pA by 1 μM GSK1016790A; the current recovered to -701.63 pA after washout. After recording I Gly , 1 μM GSK1016790A and 0.3 μM TTX were added to the ACSF and a ramp protocol that depolarized from −80 mV to +80 mV over 700 ms was applied to the same neuron to test whether GSK1016790A-evoked current could be recorded. (Fig. 2D) . The above results imply that I Gly is increased by TRPV4 agonists.
Effects of RN1734 and HC-067047 on TRPV4 agonists-induced increase of I Gly
To further determine whether TRPV4 is involved in GK1016790A-and 5, 6-EET-induced increases in I Gly , two specific TRPV4 antagonists, RN1734 (10 μM) and HC-067047 (1 μM), were used. I Gly was not affected by either RN1734 (control: -14.82±1.16 pA/pF, RN-1734: -13.79±1.55 pA/pF, n=13, paired t test, P>0.05) or HC-067047 (control: -14.62±2.99 pA/pF, HC-067047: -14.50±2.71 pA/pF, n=8, paired t test, P>0.05). Furthermore, GSK1016790A-and 5, 6-EET-induced increases in I Gly were blocked by RN1734 or HC-067047 (unpaired t test, P<0.01 in each case) (Fig. 3A and 3B) . Combined with the above result, our data indicate that I Gly is increased by activation of TRPV4.
Effects of strychnine on TRPV4 agonist-induced increase in I Gly I Gly was inhibited 95.78±0.98% by strychnine (10 μM), indicating that the present I Gly was mediated by strychnine-sensitive GlyRs. When the neurons were pre-applied with strychnine, the current was unchanged by either GSK1016790A or 5, 6-EET (Fig. 3C and  3D) . In this study, we also found that I Gly was not completely blocked by 0.1 mM picrotoxin, indicating that the GlyRs contained β subunits (Fig. 3E) . Collectively, these results imply that strychnine-sensitive GlyR function is increased by activation of TRPV4.
Intracellular signaling pathways involved in GSK1016790A-induced increase in I Gly
Studies have proven that α and β subunits of GlyRs contain sequences for phosphorylation by PKA, PKC and PTK [22] [23] [24] . We next tested whether these protein kinases were responsible Fig. 3 . Effect of TRPV4 and GlyR antagonists on TRPV4 agonist-induced increase in I Gly. A. In the presence of TRPV4 antagonist RN1734 or HC-067047, GSK1016790A-induced increase in I Gly was decreased from 34.48±2.08% (n=35) to 0.97±0.28% (n=10) and to 1.51±0.67% (n=12). Unpaired t test, ##P<0.01 vs. GSK1016790A B. 5,6-EET-induced increase in I Gly (27.71±3.10%, n=26) was attenuated by pre-application of RN1734 (0.83±0.45%, n=11) or HC-067047 (1.52±0.54%, n=10). Unpaired t test, $$P<0.01 vs. 5,6-EET C. I Gly was inhibited from -14.70±2.71 pA/pF to -0.75±0.45 pA/pF by the application of strychnine, and the current was -0.85±0.98 pA/ pF in the presence of strychnine and GSK1016790A. Paired t test, **P<0.01 vs. control D. In the presence of strychnine, the current was -0.65±0.55 pA/pF and 0.55±0.38 pA/pF before and during 5,6-EET treatment, respectively. Paired t test, **P<0.01 vs. control E. After application of 0.1 mM picrotoxin, I Gly was reduced by 76.04±1.76% from -15.01±1.41 pA/pF to -3.68±0. 41 [32] . As shown in Fig. 4A , I Gly was increased 15.30±4.91% and 13.64±2.17% by GSK1016790A in the presence of BIM or D-sphingosine, both of which were significantly different from GSK1016790A-induced increase in I Gly (unpaired t test, P<0.01). Phosphorylation by PKA has been shown to both enhance and inhibit GlyR function in different neuronal preparations [33, 34] . In this study, I Gly decreased from -15.00±1.07 pA/pF to -12.40±0.32 pA/pF when the PKA agonist 8-Br-cAMP (1 mM) was extracellularly applied (n=8, paired t test, P<0.01). I Gly increased from -14.73±1.61 pA/pF to -18.01±1.12 pA/pF (n=10, paired t test, P<0.01) and from -15.76±1.09 pA/pF to -19.74±0.37 pA/pF (n=12, paired t test, P<0.01) when the slices were exposed to PKA antagonist H-89 (10 μM) or PKI (10 μM). As shown in Fig. 4B , GSK1016790A-induced increases in I Gly were 29.31±2.17% and 33.73±1.98% after pre-application of H-89 or PKI, respectively. These increase levels were not statistically different from the increase caused by GSK1016790A alone (unpaired t test,
P>0.05).
PTK has been proven to enhance GlyR function in rat hippocampal neurons [22] . Here, in the presence of PTK antagonists lavendustin A (5 μM) or genistein (50 μM), I Gly was decreased by 17.55±3.06% (n=8, paired t test, P<0.05) and 20.01±2.89% (n=9, paired t test, P<0.01), respectively. As shown in Fig. 4C , GSK1016790A-induced increase in I Gly was not affected by pre-application of lavendustin A or genistein (unpaired t test, P>0.05). These The modulation of GlyR function by CaMKII has been described in acutely isolated rat spinal neurons [35] . As a Ca 2+ permeable channel, activation of TRPV4 induces Ca 2+ influx. In our previous study, we found that CaMKII is involved in TRPV4-induced enhancement of NMDA receptors [7] . Here, we also tested whether CaMKII signaling was responsible for the TRPV4-induced increase in I Gly . After the application of CaMKII antagonist KN62 (5 μM) or KN93 (5 μM), I Gly was reduced from -16.10±1.03 pA/pF to -11.28±0.43 pA/pF (n=8, paired t test, P<0.05) and from -15.93±1.91 pA/pF to -10.77±0.71 pA/pF (n=7, paired t test, P<0.05), respectively. As shown in Fig. 4D , with KN62 or KN93 in the pipette solution, GSK1016790A treatment increased I Gly by 10.77±1.94% or 12.41±2.94%, respectively. Both increase levels were significantly different from the increase caused by GSK1016790A alone (unpaired t test, P<0.01). These results indicate that, in addition to the PKC signaling pathway, the CaMKII signaling pathway is also involved in GSK1016790A-induced increase in I Gly .
Here, if the slices were perfused with Ca
2+
-free ACSF or pre-incubated with 10 μM BAPTA-AM, a Ca 2+ chelator, GSK1016790A treatment increased I Gly by 8.31±3.47% (n=12) and 10.91±1.65% (n=11), respectively ( Fig. 4E and 4F ). These two increase levels were significantly different from GSK1016790A-induced increase in I Gly (unpaired t test, P<0.01).
In previous studies, TRPV4 function can be modulated by phosphorylation by PKC [36] . The present study found that application of PKC antagonists BIM II and D-sphingosine reduced GSK1016790A-activated current (membrane potential=-60mV) by 10.07±2.71% (n=8, paired t test, P<0.05) and 11.34±1.17% (n=8, paired t test, P<0.05), respectively. The current was not affected by CaMKII antagonist KN62 (control: -1.24±0.09 pA/pF, KN62: -1.20±0.07 The hippocampal protein levels of GlyR α1 (A), α2 (B), α2 (C) and β (D) subunits did not change when the slices were treated with GSK1016790A for 30 min or 1 h. The protein levels of α1, α2, α3 and β GlyR subunits were first normalized to the protein levels of GAPDH, respectively and then expressed as the percentage of control values. E-H. In GSK1016790A-injected mice, the hippocampal protein levels of GlyR α2 (F), α3 (G) and β (H) subunits increased, and the protein level of α1 subunits (E) remained unchanged. The protein levels of α1, α2, α3 and β GlyR subunits were first normalized to the protein levels of GAPDH, respectively. The protein levels in GSK1016790A-injected mice were expressed as the percentage of those in vehicle-injected mice (control mice). Unpaired t test, **P<0.01 vs. control. 
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Effect of TRPV4 activation on GlyR subunits expression
Here, we examined the protein levels of GlyR α1, α2, α3 and β subunits after the hippocampal slices were treated with GSK1016790A for 30 min and 1 h. These two time points were chosen based on the acute effect of TRPV4 activation in the electrophysiology recordings. As shown in Fig. 5A-5D , the protein levels of α1, α2, α3 and β subunits in hippocampi did not changed at 30 min or 1 h after treatment with GSK1016790A (unpaired t test, P>0.05 in each case). Therefore, acute activation of TRPV4 did not affect GlyR expression.
In our previous studies, chronic activation of TRPV4 may change the expression of voltage-gated sodium channels and glutamate receptors [5, 37] . Here, hippocampal protein levels of GlyR α1, α2, α3 and β subunits were examined in GSK1016790A-injected mice. Compared to the values in vehicle-injected mice, the protein levels of α2, α3 and β subunits increased in GSK1016790A-injected mice (unpaired t test, P<0.01), while that of α1 subunit remained unchanged (Fig. 5E-5H ). This result indicates that chronic activation of TRPV4 may enhance GlyR expression.
Discussion
GABA and glycine are two major inhibitory neurotransmitters in the mammalian brain. Glycine-induced inhibitory synaptic transmission mediated by strychnine-sensitive GlyRs is well known in the spinal cord and brain stem [14, 16] . In the hippocampus, GlyRs seem not as important as GABA A Rs, for GABA A R antagonists completely abolish inhibitory postsynaptic currents. However, accumulating evidence has revealed the involvement of glycine and GlyRs in the regulation of hippocampal synapses and networks [18, 19] . Strychnine-sensitive GlyRs have been proven to be expressed in CA1 pyramidal cells in rat hippocampal slices and cultured hippocampal neurons where glycine-activated concentration-dependent currents can be recorded [38, 39] . Both α homomeric and αβ heteromeric GlyRs are present in rat hippocampal pyramidal neurons [38] . In this study, glycine-activated current was recorded in CA1 pyramidal neurons in mouse hippocampal slices and I Gly was completely blocked by strychnine, indicating that functionally strychnine-sensitive GlyRs were expressed in the mouse hippocampal pyramidal neurons. The GlyR α subunit is the obligatory subunit, which forms functional homomeric channels or heteromeric channels together with the modulatory β subunit. Picrotoxin is known to selectively block α homomeric GlyRs [29] . Here, about 20% of I Gly remained in the presence of low dose of picrotoxin (0.1 mM), indicating that GlyRs contain β subunits (Fig. 3E) . There was some differences in the concentration-response curve and I−V curve of I Gly between the previous studies and the present data, which may be due, at least in part, to the differences of recording condition (such as the pipette solution and the extracellular solution). In our recent study, hippocampal GABA A R-mediated current was blocked by activation of TRPV4 [6] . GlyR is also a chloride channel, and I Gly recorded in mouse hippocampal CA1 pyramidal neurons was unexpectedly increased by TRPV4 agonists (GSK1016790A and 5, 6-EET) (Figs. 1 and 2 ). We found that TRPV4 agonist action was blocked by the TRPV4 specific antagonists RN-1734 and HC-067047, further confirming the role of TRPV4 in the increased I Gly (Fig. 3A and 3B) . In subsequent experiments, we found that the EC 50 values in the concentration-response curves for I Gly were unchanged by GSK1016790A or 5, 6-EET (Fig. 1C and 2C) , suggesting that the TRPV4-induced increase in I Gly is likely not due to increasing the ligand-binding affinity. The I-V curves showed that the reversal voltage and I +60 mV /I −80 mV ratio were unaltered by TRPV4 agonists, indicating that the TRPV4-induced increase in I Gly is independent of the membrane voltage ( Fig. 1D and 2D) .
In this study, the protein levels of GlyR subunits did not change when the slices were perfused with GSK1016790A for 30 min to 1 h (Fig. 5A-5D ), indicating that the increase in I Gly by acute TRPV4 activation is likely due to the increase in GlyR function. Here, application of Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry PKC antagonist BIM II or D-sphingosine reduced GSK1016790A-activated current by about 10% and 11%, respectively, but in the presence of BIM II or D-sphingosine, GSK1016790A-induced increase in I Gly was attenuated by about 53% and 59%, respectively (Fig. 4 A and  4D ). Therefore, the blocking effect of PKC antagonists on GSK1016790A-induced increase was largely due to blocking the modulation on GlyR. ] i [7] . Here it was noted that GSK1016790A-induced increase in I Gly was significantly attenuated if extracellular Ca 2+ was removed or by BAPTA-AM ( Fig. 4E and 4F ), indicating that TRPV4-mediated increase in [Ca 2+ ] i is likely responsible for the increase in GlyR function caused by TRPV4 activation. At present, we did not provide the direct evidence that the enhanced PKC or CaMKII activation may be related to the TRPV4-mediated increase in [Ca 2+ ] i and more experiments are needed to clarify this possibility. The exact sequence for CaMKII phosphorylation has not been identified in GlyRs, but activation of CaMKII can increase glycine-induced currents in acutely isolated rat spinal neurons [35] . In this study, blockage of CaMKII by KN62 or KN93 decreased I Gly , also indicating that activation of CaMKII may increase I Gly in mouse hippocampal neurons. However, regarding the conditions of TRPV4 activation, it remains unclear whether activation of CaMKII phosphorylates GlyRs directly or indirectly modulates GlyRs by catalyzing its substrates.
In the hippocampus, glycine and GlyRs have been shown to mediate tonic inhibition, while GABA and GABARs are responsible for both synaptic and tonic inhibition [40] . There may be a self-homeostatic regulation of hippocampal inhibition based on the crosstalk between GlyRs and GABA A Rs [17] . Activation of both GABA A Rs and GlyRs hyperpolarizes the neuronal membrane in the adult CNS through mediating Cl -influx. When GABAergic inhibition weakens, GlyR-induced inhibition increases and thereby compensates for defects in GABAergic inhibition to a certain degree. But this compensation may be limited because of the low concentration of glycine in the cerebrospinal fluid and hippocampus [41] . On the other hand, the cross-inhibition between GlyRs and GABA A Rs attracts more researchers' attention. Activation of GlyRs can suppress the GABAergic inhibitory postsynaptic currents in the hippocampus by changing the cell input resistance or Cl -driving force [42] . A direct receptor-receptor interaction is suggested to be responsible for a state-dependent crossinhibition between GABA A Rs and GlyRs in rat hippocampal CA1 neurons [43] . In rat sacral dorsal commissural nucleus neurons, GlyRs-induced asymmetric inhibition of GABA A Rs is dependent on protein dephosphorylation caused by phosphatase 2B [21] . Activation of TRPV4 inhibited GABA A R-mediated current and the present data showed that activation of TRPV4 increased GlyRs function [6] . It is likely that the increased GlyR function revealed here may help to account for TRPV4-induced inhibition of GABA A R.
Although GlyR expression was not affected by acute TRPV4 activation, the expression of α2, α3 and β subunits were increased by sustained TRPV4 activation with the most significant increase observed for the protein level of α2 subunits (Fig. 5F, 5G and 5H ). The mature hippocampus displays relatively low expression levels of synaptic α1β-containing GlyRs, but high expression levels of extrasynaptic α2/α3-containing GlyRs [40, 44] . Therefore, it is possible that the extrasynaptic GlyR-induced tonic inhibition may be prominently affected when TRPV4 is chronically or sustainedly activated. Functional GlyRs have been detected in the spinal cord glial cells and cultured oligodendrocytes progenitors derived from cerebral cortex [45] [46] [47] . In this study, the protein levels of GlyR α2, α3 and β subunits of hippocampi were increased by GSK1016790A, but at present we could not determine the changes occurred in which type of cells (i.e. pyramidal neurons, interneurons or glial cells). More experiments are needed to clarify whether the pyramidal neuronal GlyR expression in hippocampi is specifically sensitive to chronic or sustained TRPV4 activation.
Glycine plays an important role in regulating hippocampal inhibitory/excitatory neurotransmission through activating GlyRs and acting as a co-agonist of NMDARs [17, 40] . There is no evidence about the interaction between GlyRs and NMDARs and at present we did not know whether activation of TRPV4 would affect the release of Gly in hippocampi, thereby modulating NMDARs. More experiments are needed to clarify this. GlyRs participate in self-homeostatic regulation of hippocampal inhibition through the cross-inhibition between GlyRs and GABA A Rs [17] . In this study, hippocampal GlyR function and expression were increased by TRPV4 activation. Therefore, GlyRs are effective targets for TRPV4-induced modulation of hippocampal inhibitory neurotransmission and even the neuronal excitability.
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